TTS containing an antioxidant

• US 6,316,023 B1
• Filed: 12/20/2000
• Issued: 11/13/2001
• Est. Priority Date: 01/12/1998
• Status: Expired due to Term

• Current Assignee: LTS Lohmann Therapie-Systeme GmbH, Novartis Ag
• Original Assignee: LTS Lohmann Therapie-Systeme GmbH, Novartis Ag
• Inventors: Horstmann, Michael, Asmussen, Bodo, Köpke, Kai, Tiemessen, Henricus L. G. M., Gargiulo, Paul M., Dinh, Steven Minh
• Primary Examiner(s): Clardy, S. Mark
• Assistant Examiner(s): Williamson, Michael A.
• Application Number:
  US09/747,519
• Publication Number:
  US 20010048938A1
• Time in Patent Office: 328 Days
• Field of Search: 424/449, 424/448, 602/57, 602/60, 604/290, 604/305, 604/307
• US Class Current: 424/449
• CPC Class Codes: A61K 31/27 of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
• CPC Class Codes: A61K 9/7061 Polyacrylates
• CPC Class Codes: A61K 9/7069 obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Abstract

Pharmaceutical composition comprising (S)-N-ethyl-3-[1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate in free base or acid addition salt form and an antioxidant. Said pharmaceutical compositions may be delivered to a patient using a transdermal delivery device.

Claims

1. A pharmaceutical composition comprising 1 to 40 weight percent of (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenyl carbamate in the form of a free base or acid addition salt, 0.01 to 0.5 weight percent of an antioxidant, and a diluent or carrier, wherein the weight percents are based on the total weight of the pharmaceutical composition.

2. The composition according to claim 1 wherein the antioxidant is selected from the group consisting of tocopherol, esters of tocopherol, ascorbic acid, esters of ascorbic acid, butylhydroxytoluene, butylhydroxyanisole, propyl gallate, and combinations thereof.

3. The composition according to claim 2 wherein the antioxidant is α

-tocopherol or ascorbyl palmitate.

4. The composition according to claim 1 wherein the antioxidant is present in an amount of from 0.05 to 0.2 weight percent.

5. The composition according to claim 4 wherein the antioxidant is present in an amount of from 0.1 to 0.15 weight percent.

6. A pharmaceutical composition comprising 7 to 40 weight percent of (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenyl carbamate in the form of a free base;

10 to 30 weight percent of polymethacrylate or acid addition salt;

0.05 to 0.3 weight percent of α

-tocopherol, wherein the weight percents are based on the total weight of the composition.

7. A transdermal device comprising a pharmaceutical composition comprising 1 to 40 weight percent of (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenyl carbarnate in the form of a free base or acid addition salt, 0.01 to 0.5 weight percent of an antioxidant, and a diluent or carrier, wherein the weight percents are based on the total weight of the pharmaceutical composition.

8. The transdermal device according to claim 7 further comprising an antioxidant;

a backing layer providing support for the pharmaceutical composition;

an adhesive for contacting and fixing the pharmaceutical composition to the backing layer; and

a release liner releasably contacting said adhesive.

9. The transdermal device according to claim 7 comprising a backing layer;

a layer comprising (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenyl carbamate and an antioxidant in a polymer matrix;

a release liner; and

an adhesive layer between the layer comprising (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenyl carbamate in a polymer matrix and the release liner, wherein the adhesive layer releasably fixes the transdermal device to a patients skin.